Acurx Pharmaceuticals, Inc. (ACXP) NASDAQ

4.14

-0.14(-3.27%)

Updated at September 30 11:39AM

Currency In USD

Acurx Pharmaceuticals, Inc.

Address

259 Liberty Avenue

Staten Island, NY 10305

United States of America

Phone

917-533-1469

Sector

Healthcare

Industry

Biotechnology

Employees

4

First IPO Date

June 25, 2021

Key Executives

NameTitlePayYear Born
Mr. David P. Luci CPA, Esq., J.D.Co-Founder, President, Chief Executive Officer, Corporate Secretary & Director786,8831967
Mr. Robert G. Shawah CPACo-Founder & Chief Financial Officer533,6531967
Mr. Robert J. DeLucciaCo-Founder & Executive Chairman818,9301946

Description

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.